A Study to Evaluate the Safety and Clinical Efficacy of STR-P004

NCT07003178 | Not Yet Recruiting Early Phase 1

• 1 other identifier: Starna Therapeutics P004
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a single-arm, single-center, open-label, multiple-dose, dose-escalation early clinical study aimed at evaluating the safety, tolerability, and pharmacokinetic profile of STR-P004 in subjects with relapsed/refractory CD19-positive B-cell non-Hodgkin lymphoma, and preliminarily observing its antitumor activity.

Conditions

Non Hodgkin Lymphoma

Outcome Measures

Primary Outcomes (1)

• In accordance with the (US) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and the ASTCT consensus. The incidence of DLT events in this trial.

  DLTs in this trial are defined as dose-escalation phase, toxic reactions related to the study drug (including definitely related, probably related, and possibly related) that occur from the time of first receipt of STR-P004 IV infusion to the end of the first treatment cycle (i.e., D1\~ D28), and primarily include hematologic and non-hematologic toxicities. \> Hematologic DLT: \- Grade 4 neutropenia does not return to ≤ grade 2 or baseline status within 28 days of G-CSF (granulocyte colony-stimulating factor) treatment and excludes involvement/infiltration due to the disease itself; \- Grade 4 thrombocytopenia that does not return to grade ≤2 or baseline status within 28 days of rhTPO/TPO-RA (recombinant human thrombopoietin and thro

  24 months

Study Arms (5)

Dose1

EXPERIMENTAL

STR-P004 Dose1 IV

Drug: STR-P004

Dose2

EXPERIMENTAL

STR-P004 Dose2 IV

Drug: STR-P004

Dose 3

EXPERIMENTAL

STR-P004 Dose3 IV

Drug: STR-P004

Dose4

EXPERIMENTAL

STR-P004 Dose4 IV

Drug: STR-P004

Dose5

EXPERIMENTAL

STR-P004 Dose5 IV

Drug: STR-P004

Interventions

STR-P004 DRUG

An in vivo CART drug administered intravenously

Dose 3; Dose1; Dose2; Dose4; Dose5

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects with relapsed/refractory CD19-positive B-cell non-Hodgkin's lymphoma:
• Age ≥18 years, regardless of gender;
• Life expectancy \>12 weeks;
• ECOG score of 0-2;
• Diagnosis of B-cell non-Hodgkin's lymphoma confirmed by cytology or histopathology according to WHO 2016 criteria, including: diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL), and high-grade B-cell lymphoma (HGBCL);
• Pathologically confirmed B-cell non-Hodgkin's lymphoma meeting one of the following conditions:
• Relapsed/refractory B-cell non-Hodgkin's lymphoma with the best response of SD or PD after receiving at least two lines of adequate therapy, the best response of PD during or after the last line of treatment, or the best response of SD after receiving at least two cycles of the last line of treatment;
• For relapse or PD within 12 months after autologous stem cell transplantation (ASCT) for B-cell non-Hodgkin's lymphoma, if salvage therapy is administered, no response (SD/PD) to the last treatment is required; for relapse or PD more than 12 months after ASCT, salvage therapy is needed, and no response (SD/PD) to the last treatment is required;
• Hemoglobin ≥80 g/L, neutrophils ≥1.0 × 109/L, platelets ≥75 × 109/L;
• At least one measurable tumor lesion according to the 2014 Lugano response criteria;
• Hepatic and renal function, as well as cardiopulmonary function, meet the following requirements:
• Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min (calculated by the Cockcroft-Gault formula);
• Ejection fraction \>50%, with no clinically significant pericardial effusion or pleural effusion detected;
• Baseline oxygen saturation \>92%;
• Total bilirubin ≤1.5 × ULN (≤5 × ULN for Gilbert syndrome);

You may not qualify if:

• Subjects meeting any of the following conditions will not be eligible for participation:
• History of malignancies other than diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL), or high-grade B-cell lymphoma (HGBCL) within 5 years prior to screening, except for adequately treated cervix carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery, or thyroid cancer after radical surgery;
• Presence of any of the following high-risk factors: sum of product of diameters (SPD) of lesions (all measurable lesions ≥1.5 cm in the longest diameter) ≥100 cm; bulky disease (single lesion ≥10 cm); lesions located in the pharynx or trachea with pressure symptom; lesions adjacent to critical hollow organs such as the gastrointestinal tract or bile ducts, where enlargement may press or invade surrounding organs and impair their functions;
• Subjects who have not completed a washout period of at least 5 half-lives since their last anticancer therapy (including I/O therapy) prior to the first dose of study treatment; for anticancer therapies with a half-life \>5 days, a washout period \>14 days is acceptable; or participation in any other clinical study within 4 weeks prior to the first treatment;
• Any of the following conditions: positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B e antigen (HBeAg); positive for hepatitis B e antibody (HBe-Ab) with HBV-DNA copy number above the lower limit of detection; positive for hepatitis C antibody (HCV-Ab); positive for anti-Treponema pallidum antibody (TP-Ab); positive for human immunodeficiency virus (HIV) antibody; EBV-DNA or CMV-DNA copy number above the lower limit of detection;
• Any unstable systemic disease, including but not limited to active infection (except for local infections), unstable angina, cerebrovascular accident or transient ischemic attack (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association \[NYHA\] class ≥III), severe arrhythmia requiring medication, or hepatic, renal, or metabolic disorders;
• Any uncontrolled active condition that may interfere with study participation;
• Any condition deemed by the investigator to compromise subject safety or interfere with the study objective;
• Pregnant or breastfeeding women, or subjects who plan to become pregnant during the treatment period or within 1 year after treatment completion, or male subjects whose partners plan to become pregnant within 1 year after cell infusion;
• Subjects receiving systemic corticosteroid therapy within 14 days prior to enrollment and judged by the investigator to require long-term use of systemic corticosteroid during treatment (excluding inhaled or topical use);
• Presence of central nervous system or brain metastasis symptoms or receiving treatment for central nervous system or brain metastasis (radiotherapy, surgery, or other therapy) within 3 months prior to enrollment;
• Subjects with conditions that impair their ability to provide written informed consent or comply with study procedures, or those unwilling or unable to adhere to study requirements.
• Subjects deemed unsuitable for participation in this study by the investigator.

Sponsors & Collaborators

• Starna Therapeutics: lead

Study Sites (1)

Starna

Suzhou, Jiangsu, 215123, China

Location

MeSH Terms

Conditions

Lymphoma, Non-Hodgkin

Condition Hierarchy (Ancestors)

Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Central Study Contacts

Li Jing Shi

CONTACT

+8618896505123; shijingli@starnatx.com

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 19, 2025
• First Posted: June 4, 2025
• Study Start: June 1, 2025
• Primary Completion: April 1, 2026
• Study Completion (Estimated): May 1, 2027
• Last Updated: June 4, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)